Document is current
Any future updates will be listed below
-
Authors
Wu, Qi
Hatse, Sigrid
Kenis, Cindy
Fernández-García, Juan
Altea-Manzano, Patricia
Billen, Jaak
Planque, Mélanie
Vandekeere, Anke
Lambrechts, Yentl
Richard, François
Punie, Kevin
Neven, Patrick
Smeets, Ann
Nevelsteen, Ines
Floris, Giuseppe
Desmedt, Christine
Gomes, Ana P.
Fendt, Sarah-Maria
Wildiers, Hans https://orcid.org/0000-0001-8990-7837
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek
European Resuscitation Council (n. 771486)
National Coronial Information System (R00CA218686)
- License Information
-
More Information
Article History
Received: 16 May 2023
Accepted: 18 January 2024
First Online: 13 March 2024
Declarations
:
: S-MF has received funding from Bayer AG, Merck, Black Belt Therapeutics, Gilead and Alesta Therapeutics, has consulted for Fund + , and is in the advisory board of Alesta Therapeutics. KP: Research grants to institute: MSD and Sanofi. Speaker fees and honoraria for consultancy and advisory board functions: Astra Zeneca, Eli Lilly, Exact Sciences, Focus Patient, Gilead, MSD, Novartis, Pfizer, Roche, Seagen. Speaker fees and honoraria for consultancy and advisory board functions to institution: Astra Zeneca, Eli Lilly, Exact Sciences, Gilead, MSD, Novartis, Pfizer, Roche, Seagen. Stock options: Need Inc. Travel grants from Astra Zeneca, Novartis, Pfizer, PharmaMar, Roche. Other authors declare that they have no competing interests.
